Knockdown of CCND1 inhibited glioblastoma cell proliferation and invasion by simultaneously targeting multidrug resistance protein 1 (MDR1), B-cell lymphoma-2 (Bcl-2), and caspase-3 [52]. This evidence concerns the gene BCL2 and glioblastoma.